FDA approves virtual colonoscopy fecal tagging agent — 3 insights

The FDA approved Bracco Diagnostics' Tagitol V oral suspension for adult patients undergoing virtual colonoscopy.

Here's what you should know:

1. The low-volume fecal tagging agent opacifies residual stool in the colon to facilitate CT imaging.

2. The agent blends into the stool, allowing physicians to immediate identify retained feces.

3. By tagging residual particles, physicians can better identify polyps from stool, helping to decrease the amount of false positives.

Bracco Diagnostics Vice President of Marketing James Moran said in a release, "Bracco has been a leading proponent of the development of CTC and developed Tagitol V contrast to help physicians make an accurate diagnosis. … Bracco remains committed to offer products that meet critical diagnostic needs and to provide education to both healthcare professionals and patients."

More articles on gastroenterology: 
GI leader to know: Dr. Daryl M. McClendon of Alaska Digestive and Liver Disease Clinic
12 statistics on gastroenterologist salary — $357k is median
Penn State College of Medicine taps Dr. Thomas Ma for chairmanship — 4 key notes

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months